ASCO 2019 | EV-201: enfortumab vedotin for bladder cancer

Daniel Petrylak • 2 Jun 2019

Bladder Cancer Genitourinary Cancer Enfortumab vedotin

Daniel Petrylak, MD, of the Yale School of Medicine, New Haven, CT, tells about the EV-201 bladder cancer study (NCT03219333) which investigated enfortumab vedotin for patients with locally advanced or metastatic urothelial bladder cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

ARCHES: OS in mHSPC who recieved prior ADT and reached low PSA further treated with enzalutamide

Daniel Petrylak • 11 Sep 2022

PSMA ADC in prostate cancer: Phase I results

Daniel Petrylak • 15 Feb 2019

RANGE study: Ramucirumab plus docetaxel improves PFS in advanced or metastatic urothelial cancer

Daniel Petrylak • 10 Sep 2017

HER2-targeting ADCs for urothelial carcinoma

Daniel Petrylak • 3 Jun 2023

Related Videos

Improving the current chemotherapy standard: a role for DNA methyltransferase inhibitors

Simon Crabb • 16 Nov 2018

Adverse events in bladder cancer immunotherapy

Jonathan Rosenberg • 18 Jan 2019

How to involve patients in clinical decision making

Joe O'Sullivan • 29 Nov 2018

Cabozantinib plus docetaxel and prednisone in mCRPC

Munjid Al Harthy • 18 Feb 2019